Related references
Note: Only part of the references are listed.Low Urine Secretion of Semaphorin3A in Lupus Patients with Proteinuria
Rimar Doron et al.
INFLAMMATION (2022)
Semaphorin 3A Levels in Lupus With and Without Secondary Antiphospholipid Antibody Syndrome and Renal Involvement
Gozde Sevgi Kart Bayram et al.
LABORATORY MEDICINE (2022)
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Gerald Simonneau et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Role of Semaphorins in Immunopathologies and Rheumatic Diseases
Samuel Garcia
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Semaphorin3A: A Potential Therapeutic Tool for Lupus Nephritis
Jacob Bejar et al.
FRONTIERS IN IMMUNOLOGY (2018)
Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis
Francesca Ingegnoli et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2018)
Evidence for a Derangement of the Microvascular System in Patients with a Very Early Diagnosis of Systemic Sclerosis
Ines Chora et al.
JOURNAL OF RHEUMATOLOGY (2017)
Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis
Eloisa Romano et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Semaphorin 3A: an immunoregulator in systemic sclerosis
Doron Rimar et al.
RHEUMATOLOGY INTERNATIONAL (2015)
Autoantibodies in systemic sclerosis: unanswered questions
Cristiane Kayser et al.
FRONTIERS IN IMMUNOLOGY (2015)
Serum Angiopoietin-like Protein 3 Levels: Possible Correlation with Progressive Skin Sclerosis, Digital Ulcers and Pulmonary Vascular Involvement in Patients with Systemic Sclerosis
Yohei Ichimura et al.
ACTA DERMATO-VENEREOLOGICA (2014)
Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis
Murray Baron et al.
CLINICAL RHEUMATOLOGY (2014)
Review: Evidence That Systemic Sclerosis Is a Vascular Disease
Marco Matucci-Cerinic et al.
ARTHRITIS AND RHEUMATISM (2013)
2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Frank van den Hoogen et al.
ARTHRITIS AND RHEUMATISM (2013)
Decreased Semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis
Shu Takagawa et al.
BMC MUSCULOSKELETAL DISORDERS (2013)
The role of semaphorins and their receptors in vascular development and cancer
Chenghua Gu et al.
EXPERIMENTAL CELL RESEARCH (2013)
Clinical significance of circulating platelet-activating factor acetylhydrolase levels in systemic sclerosis
Koichi Yanaba et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2012)
Semaphorin 3A-a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus
Z. Vadasz et al.
LUPUS (2012)
Association of C-reactive protein with high disease activity in systemic sclerosis: Results from the Canadian Scleroderma Research Group
Chayawee Muangchan et al.
ARTHRITIS CARE & RESEARCH (2012)
Class 3 semaphorins and their receptors in physiological and pathological angiogenesis
Carolyn A. Staton
BIOCHEMICAL SOCIETY TRANSACTIONS (2011)
The Neuroimmune Semaphorin-3A Reduces Inflammation and Progression of Experimental Autoimmune Arthritis
Alfonso Catalano
JOURNAL OF IMMUNOLOGY (2010)
Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis
Noga Guttmann-Raviv et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function
A Catalano et al.
BLOOD (2006)
European multicentre study to define disease activity criteria for systemic sclerosis.: I.: Clinical and epidemiological features of 290 patients from 19 centres
A Della Rossa et al.
ANNALS OF THE RHEUMATIC DISEASES (2001)